Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Procainamide-induced myositis

E S Fontiveros, W J Cumming, P Hudgson

    Journal of the Neurological Sciences
    |February 1, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Procainamide can cause lupus-like symptoms and myopathy. This case highlights a severe vasculitis linked to procainamide, which improved after drug withdrawal and treatment, suggesting a drug-induced autoimmune response.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Identification and expression analysis of spastin gene mutations in hereditary spastic paraplegia.

    American journal of human genetics·2001
    Same author

    A novel autosomal dominant distal myopathy with early respiratory failure: clinico-pathologic characteristics and exclusion of linkage to candidate genetic loci.

    Annals of neurology·2001
    Same author

    Symptomatic lumbar spinal arachnoiditis: fact or fallacy?

    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2000
    Same author

    Locus heterogeneity, anticipation and reduction of the chromosome 2p minimal candidate region in autosomal dominant familial spastic paraplegia.

    Neurogenetics·2000
    Same author

    First there was the bandage...

    The Medical journal of Australia·2000
    Same author

    A sartorial challenge.

    Lancet (London, England)·1999
    Same journal

    Distinguishing drug-target effects from natural lipid variation and incorporating imaging outcomes in Mendelian randomisation studies of multiple sclerosis.

    Journal of the neurological sciences·2026
    Same journal

    Long-term social cognitive impairment after ischemic stroke: Frequency and association with lesion volume and location in an exploratory pilot study.

    Journal of the neurological sciences·2026
    Same journal

    Subjective cognitive decline among U.S. Cancer survivors, 2017-2024: Prevalence, cancer-specific patterns, and associated factors.

    Journal of the neurological sciences·2026
    Same journal

    Comment on "Comparative impact of mental and cardiovascular comorbidities on adverse outcomes in people with MS".

    Journal of the neurological sciences·2026
    Same journal

    Comment on "Efficacy and safety of conventional immunosuppressant therapies in elderly patients with Neuromyelitis optica spectrum disorder: A target trial emulation study".

    Journal of the neurological sciences·2026
    Same journal

    Increasing incidence of varicella-zoster virus meningitis in Japan, 2011-2022.

    Journal of the neurological sciences·2026
    See all related articles

    Area of Science:

    • Rheumatology
    • Clinical Pharmacology
    • Neurology

    Background:

    • Procainamide is known to induce a lupus-like syndrome.
    • Drug-induced myopathy is a rare complication of procainamide therapy.
    • Previous reports of myopathy lacked histopathological evidence of inflammation.

    Purpose of the Study:

    • To report a case of severe, rapidly progressive myopathy associated with procainamide use.
    • To investigate the potential link between procainamide and drug-induced vasculitis affecting muscle.
    • To describe the treatment and outcome of this rare adverse drug reaction.

    Main Methods:

    • Case report of a patient with myopathy after long-term procainamide use.
    • Clinical assessment for systemic lupus erythematosus (SLE) and muscle inflammation.

    Related Experiment Videos

  • Immunological testing to support autoimmune diagnosis.
  • Monitoring of symptoms after drug withdrawal and treatment.

    • Main Results:

    • The patient developed severe myopathy and vasculitis after 42 months of procainamide.
    • Muscle symptoms rapidly improved upon discontinuation of procainamide.
    • Azathioprine treatment facilitated the remission of myopathy.
    • Significant immunological evidence supported a diagnosis resembling SLE, despite no clinical SLE features.

    Conclusions:

    • Procainamide can induce severe myopathy and vasculitis, mimicking autoimmune conditions.
    • Early recognition and drug withdrawal are crucial for managing procainamide-induced myopathy.
    • Immunosuppressive therapy may be beneficial in resolving these drug-induced autoimmune phenomena.